Pathogen News and Research

RSS

Comprehensive analysis of antibody responses in COVID-19 patients can help develop effective vaccine

A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.

11 Sep 2020

New book gives overview of viruses and how they emerge to cause pandemics

Since the novel coronavirus SARS-Cov-2 emerged late last year, it has been virtually impossible to consume any news without encountering stories about the virus and how it spreads, potential treatments, and the development of new vaccines.

11 Sep 2020

Study shows role of pathogens in shaping human evolution

Every human cell harbors its own defenses against microbial invaders, relying on strategies that date back to some of the earliest events in the history of life, researchers report.

10 Sep 2020

Allergic immune response against bacteria is not pathological but protective

Allergy is one of the most common diseases in Europe, it is estimated that more than 150 million Europeans suffer from recurring allergies and by 2025 this could have increased to half of the entire European population.

9 Sep 2020

Brain inflammation seen in fatal COVID-19 cases

Now, a new study by researchers at the Barts Health NHS Trust and the University of Cambridge in the United Kingdom shows that some patients develop neurological complications tied to COVID-19.

9 Sep 2020

Researchers receive $1.9 million federal grant to find Lyme disease vaccine

Pesky, yet dangerous ticks are no longer latching exclusively onto hunters and outdoor enthusiasts. Milder winters and disrupted habitats have driven them out of the woods, with Lyme disease cases in the United States tripling since the late 1990s.

9 Sep 2020

'Molecular brake' on the immune system could be potential treatment target for severe COVID-19

Older people and people with underlying medical conditions are at particular risk of severe COVID-19. A group of researchers from Charité - Universitätsmedizin Berlin have discovered one possible reason for this vulnerability.

8 Sep 2020

Memory B cells indicate durable immunity in COVID-19

Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.

8 Sep 2020

Antibody-mediated platelet death linked to COVID-19 severity

A new study by University of Tuebingen researchers shows the strong association between platelet apoptosis and the thrombotic manifestations that may underlie critical COVID-19 illness.

7 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

Rehabilitation speeds coronavirus recovery

Now, a team of researchers at the University Clinic in Innsbruck in Austria has found that the long-term lung and heart damage in coronavirus disease (COVID-19) patients who recovered tend to improve over time.

7 Sep 2020

Seasonal influenza and COVID-19 risk

In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).

6 Sep 2020

Study shows fatty liver disease is a significant risk factor for COVID-19 hospitalization

A recent observational study by US researchers reveals that individuals with non-alcoholic fatty liver disease and steatohepatitis have increased odds of hospitalization due to coronavirus disease (COVID-19); conversely, metabolic surgery was found to be protective against the admission of infected individuals. The study is currently available on the medRxiv* preprint server.

3 Sep 2020

Research provides a map of coronavirus entry factors across the human body

An infection with the coronavirus SARS-CoV-2 can affect multiple organs. With this in mind, researchers of the German Center for Neurodegenerative Diseases and Cornell University in the US have investigated cellular factors that could be significant for an infection.

3 Sep 2020

COVID-19 vaccine candidate protects animals against SARS-CoV-2

Most people with COVID-19 have relatively mild disease, but a subset of people develop severe pneumonia and respiratory failure, potentially leading to death.

3 Sep 2020

Two MDC scientists win ERC Starting Grants for pioneering research

Dr. Kathrin de la Rosa and Dr. Ilaria Piazza, who are both junior group leaders at the Max DelbruÌ-ck Center for Molecular Medicine in the Helmholtz Association, have each won European Research Council Starting Grants.

3 Sep 2020

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests.

3 Sep 2020

Genomic analysis of specific E. coli strain can help develop potential vaccines

Foodborne pathogens are very common and usually benign, but certain virulent strains of pathogens can result in severe disease and even death.

3 Sep 2020

Study identifies subtypes and developmental process of novel immune T cells

There are memory cells that remember previously encountered pathogens and help to react quickly and strongly when exposed to them again.

2 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020